JNJ-75229414 for Prostate Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called JNJ-75229414 to find the safest and most effective dose for patients. The study will identify the best dose and ensure it is safe.
Research Team
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Eligibility Criteria
This trial is for men with advanced prostate cancer that has spread and doesn't respond to hormone therapy. They should have tried at least one other treatment like abiraterone or chemotherapy, be relatively healthy (ECOG grade 0 or 1), and either have measurable disease or detectable PSA levels. Men must use contraception during the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive a conditioning regimen of cyclophosphamide and fludarabine followed by JNJ-75229414 IV infusion to determine recommended Phase 2 dose (RP2D) regimen(s)
Dose Expansion
Participants receive JNJ-75229414 for each RP2D regimen determined in Part 1
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- JNJ-75229414
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Giacomo Salvadore
Janssen Research & Development, LLC
Chief Medical Officer since 2023
MD from the University of Rome, Tor Vergata
Ricardo Attar
Janssen Research & Development, LLC
Chief Executive Officer since 2008
PhD in Molecular Biology from the University of Buenos Aires